Parameters | Empagliflozin (N = 271) | DPP-4 Inhibitors (N = 331) | Rate Ratio |
Incidence of DKA with metformin | |||
Patients with events in the period, n (%) | 1 (0.4) | 1 (0.3) |
|
Crude incidence rate | 0.004 | 0.003 | 1.333 |
(95% confidence interval) | (0, 0.020) | (0, 0.017) |
|
Treatment-adjusted incidence rate |
|
|
|
(crude per 1000 patient-years) | 1.380 | 1.407 | 0.981 |
(95% confidence interval) | (0.035, 7.690) | (0.036, 7.842) |
|
Incidence of volume depletion with metformin | |||
Patients with events in the period, n (%) | 3 (1.1) | 4 (1.2) |
|
Patients without event, n (%) | 268 (98.9) | 327 (98.8) |
|
Crude incidence rate | 0.011 | 0.012 | 0.917 |
(95% confidence interval) | (0.002, 0.032) | (0.003, 0.031) |
|
Treatment-adjusted incidence rate |
|
|
|
(crude per 1000 patient-years) | 4.141 | 5.630 | 0.736 |
(95% confidence interval) | (0.854, 12.101) | (1.534, 14.415) |
|
Time from start of period to first occurrence in period (days) | 76.7 ± 15 | 225 ± 137.9 |
|
| Empagliflozin (N = 480) | DPP-4 Inhibitors (N = 420) | Rate Ratio |
Incidence of volume depletion without metformin | |||
Patients with events in the period, n (%) | 3 (0.6) | 3 (0.7) |
|
Patients without event, n (%) | 477 (99.4) | 417 (99.3) |
|
Crude incidence rate | 0.006 | 0.007 | 0.857 |
(95% confidence interval) | (0.001, 0.018) | (0.001, 0.021) |
|
Treatment-adjusted incidence rate |
|
|
|
(crude per 1000 patient-years) | 4.141 | 4.222 | 0.981 |
(95% confidence interval) | (0.854, 12.101) | (0.871, 12.340) |
|
Time from start of period to first occurrence in period (days) | 261.3 ± 130.8 | 297.7 ± 60 |
|